RATIONALE: There is an extensive literature showing that the CB(1) cannabinoid receptor antagonist rimonabant (SR141716) decreases alcohol consumption in animals, but little is known about its effects in human alcohol drinkers. METHODS: In this study, 49 nontreatment-seeking heavy alcohol drinkers participated in a 3-week study. After a 1-week baseline, participants received either 20 mg/day of rimonabant or placebo for 2 weeks under double-blind conditions. During these 3 weeks, participants reported their daily alcohol consumption by telephone. Subsequently, they participated in an alcohol self-administration paradigm in which they received a priming dose of alcohol followed by the option of consuming either eight alcohol drinks or receiving $3.00 for each nonconsumed drink. Endocrine measures and self-rating scales were also obtained. RESULTS: Rimonabant did not change alcohol consumption during the 2 weeks of daily call-ins. Similarly, the drug did not change either alcohol self-administration or endocrine measures during the laboratory session. CONCLUSION: We conclude that the daily administration of 20 mg of rimonabant for 2 weeks has no effect on alcohol consumption in nontreatment-seeking heavy alcohol drinkers.
RCT Entities:
RATIONALE: There is an extensive literature showing that the CB(1) cannabinoid receptor antagonist rimonabant (SR141716) decreases alcohol consumption in animals, but little is known about its effects in humanalcohol drinkers. METHODS: In this study, 49 nontreatment-seeking heavy alcohol drinkers participated in a 3-week study. After a 1-week baseline, participants received either 20 mg/day of rimonabant or placebo for 2 weeks under double-blind conditions. During these 3 weeks, participants reported their daily alcohol consumption by telephone. Subsequently, they participated in an alcohol self-administration paradigm in which they received a priming dose of alcohol followed by the option of consuming either eight alcohol drinks or receiving $3.00 for each nonconsumed drink. Endocrine measures and self-rating scales were also obtained. RESULTS:Rimonabant did not change alcohol consumption during the 2 weeks of daily call-ins. Similarly, the drug did not change either alcohol self-administration or endocrine measures during the laboratory session. CONCLUSION: We conclude that the daily administration of 20 mg of rimonabant for 2 weeks has no effect on alcohol consumption in nontreatment-seeking heavy alcohol drinkers.
Authors: M Arnone; J Maruani; F Chaperon; M H Thiébot; M Poncelet; P Soubrié; G Le Fur Journal: Psychopharmacology (Berl) Date: 1997-07 Impact factor: 4.530
Authors: Panayotis K Thanos; Elias S Dimitrakakis; Onarae Rice; Andrew Gifford; Nora D Volkow Journal: Behav Brain Res Date: 2005-11-07 Impact factor: 3.332
Authors: Andrea Cippitelli; Ainhoa Bilbao; Anita C Hansson; Ignacio del Arco; Wolfgang Sommer; Markus Heilig; Mauricio Massi; Francisco Javier Bermúdez-Silva; Miguel Navarro; Roberto Ciccocioppo; Fernando Rodríguez de Fonseca Journal: Eur J Neurosci Date: 2005-04 Impact factor: 3.386
Authors: José Antonio López-Moreno; Gustavo González-Cuevas; Fernando Rodríguez de Fonseca; Miguel Navarro Journal: J Neurosci Date: 2004-09-22 Impact factor: 6.167
Authors: J Hirvonen; P Zanotti-Fregonara; J C Umhau; D T George; D Rallis-Frutos; C H Lyoo; C-T Li; C S Hines; H Sun; G E Terry; C Morse; S S Zoghbi; V W Pike; R B Innis; M Heilig Journal: Mol Psychiatry Date: 2012-07-10 Impact factor: 15.992
Authors: Suchitra Krishnan-Sarin; Stephanie S O'Malley; Nicholas Franco; Dana A Cavallo; Meghan Morean; Julia Shi; Brian Pittman; John H Krystal Journal: Alcohol Clin Exp Res Date: 2015-02-09 Impact factor: 3.455
Authors: K Yaragudri Vinod; Paola Maccioni; Maria Salud Garcia-Gutierrez; Teresa Femenia; Shan Xie; Mauro A M Carai; Jorge Manzanares; Thomas B Cooper; Basalingappa L Hungund; Giancarlo Colombo Journal: Addict Biol Date: 2011-02-11 Impact factor: 4.280
Authors: Martin H Plawecki; Leah Wetherill; Victor Vitvitskiy; Ann Kosobud; Ulrich S Zimmermann; Howard J Edenberg; Sean O'Connor Journal: Alcohol Clin Exp Res Date: 2012-07-20 Impact factor: 3.455
Authors: Rose-Marie Karlsson; Louise Adermark; Anna Molander; Stephanie Perreau-Lenz; Erick Singley; Matthew Solomon; Andrew Holmes; Kohichi Tanaka; David M Lovinger; Rainer Spanagel; Markus Heilig Journal: Neuropharmacology Date: 2012-02-09 Impact factor: 5.250